Updates are available Correction dated 2019-10-09
Click to view Correction: https://doi.org/10.1007/s00415-019-09549-w
-
Authors
Colosimo, Carlo http://orcid.org/0000-0002-2216-3973
,
Charles, David
Misra, Vijay P.
Maisonobe, Pascal
Om, Savary
-
Funding
Funding for this research was provided by:
Ipsen Pharma
- License Information
-
More Information
Article History
Received: 25 July 2019
Revised: 2 September 2019
Accepted: 3 September 2019
First Online: 9 September 2019
Change Date: 9 October 2019
Change Type: Correction
Change Details: The article How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment?
Compliance with ethical standards
:
: Prof C Colosimo reports consultancy for Ipsen, Merz, Abbvie, BIAL, Zambon and UCB. Vanderbilt University receives income from Abbott, Allergan, Boston Scientific, Ipsen, Lundbeck, Merz, Medtronic, and US WorldMeds for research or educational programs led by Dr D Charles. Dr D Charles receives income from Allergan, Ipsen, Revance, US WorldMeds, and the Alliance for Patient Access for education or consulting services. Dr VP Misra report consultancy for Ipsen. P Maisonobe & Dr S Om are Ipsen employees.
: The study was conducted in compliance with the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP). Independent Ethics Committee/Institutional Review Board approval was obtained prior to each centre initiation.
: Written informed consent was obtained prior to subject enrolment and performance of any study procedures.
